英國藥廠葛蘭素史克季績勝預期 上調全年盈測
英國藥廠葛蘭素史克(GSK)第三季按固定匯率計經調整後每股盈利增長10%至36.6便士優於市場預期。收入按年增長10%至91億英鎊,高於市場預期的87億英鎊。
葛蘭素史克預計全年每股盈利僅下跌2至4個百分點,好於之前預測的中高單位數的跌幅。
葛蘭素史克表示,在疫情緩和後Shingrix生蛇疫苗需求反彈,上季銷售急增41%至5.02億英鎊,預計隨着Shingrix生蛇疫苗需求續增,有信心在5年內收入增長一倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.